Komori
Solasia Pharma K.K. (4597) · InitiativeAdvanced

Collaborative development of SP-05 through an investment in Isofol

First written in FY2025. 3 of 4 entries say "Advanced", first in 2026-05-15. Latest entry: FY2026-H1.

4entries
1years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2025Advanced2026-05-15 – FY2026-H12026: 42026
Same theme, other companies
Collaborative development of SP-05 through an investment in IsofolA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2026-H1AdvancedAnnual report

    「Following a request for investment, we acquired shares in Isofol for ¥77 million in July 2025 and ¥34 million in March 2026.」

    SP-05の開発再開に伴うIsofol社との連携について、2025年7月の77百万円に続き、2026年3月に34百万円の同社株式取得を実施した。
  3. FY2025First statedAnnual report

    「Isofol decided to raise funding for future SP-05 development through a rights offering and other methods. Following a request for investment, the Company invested ¥77 million in July 2025.」

    In connection with the resumption of SP-05 development, the Company invested ¥77 million at the request of rights licensor Isofol. The Company stated that the investment would support close cooperation with Isofol and allow it to benefit from the economic value arising from development progress outside Japan.
Moved together

"SP-01: Sancuso® Approved and Launched in China" moved the same way as this thread, in the same document, in 3 of its 4 moves.

333222★123456
  1. ★This thread
  2. 1SP-01: Sancuso® Approved and Launched in China3×
  3. 2Building Strong Sales Partnerships3×
  4. 3Funding to Maintain the Business Foundation and Continue Development3×
  5. 4SP-03 episil® Regulatory Approval and Launch in Japan and China2×
  6. 5Combined Use of the China Direct-Sales Model and Derived Models for Other Regions2×
  7. 6In-Licensing of Japanese Development and Commercialization Rights for SP-05 arfolitixorin2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Solasia Pharma K.K. yet. It last moved in the Financial Results Presentation of 2026-05-15: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Collaborative development of SP-05 through an investment in Isofol | Solasia Pharma K.K. (4597) | Komori